Science & Technology Review
|
2019, 37(24): 51-56
• Exclusive: Introductions of the Nobel Prizes in Science 2019 •
New progress of hypoxia inducible factor in the treatment of diseases
Full
LI Han, LU Xiangxue
Affiliations
Department of Blood Purification, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China
Published: 2019-12-28
doi: 10.3981/j.issn.1000-7857.2019.24.007
Outline
The hypoxia inducible factor (HIF) is a heterodimer DNA-binding transcription factor that can bind with specific nuclear cofactors and activate a variety of genes to optimize the oxygen utilization under hypoxia conditions. The American oncologist William G. Kaelin Jr., the British medical scientist Sir Peter J. Ratcliffe and the American medical scientist Gregg L. Semenza won the 2019 Nobel Prize in Physiology or Medicine for discovering how cells sense and adapt to the oxygen availability where the HIF plays an important role. This paper reviews the research progress of the HIF in the treatment of renal anemia, tumor, cardiovascular disease, as well as its significance to human health.
hypoxia-inducible factor
/
Nobel Prize in Physiology or Medicine 2019
/
renal anemia
/
tumor
/
cardiovascular disease
李寒, 路香雪.
低氧诱导因子在疾病治疗中的新进展——2019年诺贝尔生理学或医学奖成果简析.
科技导报,
2019
, 37
(24)
: 51
-56
.
DOI: 10.3981/j.issn.1000-7857.2019.24.007
LI Han, LU Xiangxue.
New progress of hypoxia inducible factor in the treatment of diseases[J].
Science & Technology Review,
2019
, 37
(24)
: 51
-56
.
DOI: 10.3981/j.issn.1000-7857.2019.24.007
Year 2019 volume 37 Issue 24
PDF
840
450
Cite this Article
BibTeX
Article Info
doi: 10.3981/j.issn.1000-7857.2019.24.007
- Receive Date:2019-11-04
- Online Date:2020-01-02
- Published:2019-12-28